The World Health Organization strongly discourages the use of blood plasma of recovered Covid19 patients as treatment for infected persons with mild or moderate illness.
While early research suggested good results for administering convalescent plasma intravenously to infected patients, the WHO recently declared that “current evidence shows that it does not improve survival nor reduce the need for mechanical ventilation, and it is costly and time-consuming to administer.”
It also said that even for severely or critically ill patients, treatment with convalescent plasma should only be done as part of a critical trial.
The health body drew their latest recommendations from 16 trials with 16,236 patients with non-severe, severe and critical infection.
Convalescent plasma is the liquid part of blood of a person who has recovered from Covid19. This contains antibodies that the body produced after getting infected. Its use was considered among a number of potential treatments early on in the pandemic but has since shown little benefit in clinical trials.